Shafik et al. revealed that METTL3 is downregulated in the hippocampus in Alzheimer’s disease (AD) patients and that the levels of METTL3 and m6A modification of AD-related mRNAs are also reduced in 5XFAD mice [15], while upregulation of METTL3 can promote STUB1 gene expression through an m6A-IGF2BP1-dependent mechanism involving stabilisation of STUB1 mRNA and promotion of autophagic p-Tau clearance in Aβ1-42-treated cells, thus improving AD [16]. The gene discussed is METTL3; the disease is Alzheimer disease.